{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T22:24:02Z","timestamp":1789770242161,"version":"4.0.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T00:00:00Z","timestamp":1715212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T00:00:00Z","timestamp":1715212800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1007\/s12325-024-02853-6","type":"journal-article","created":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T07:02:25Z","timestamp":1715238145000},"page":"2757-2775","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Development of a Conceptual Model of Physical Functioning Limitations Experienced by Patients with Late-Stage Chronic Kidney Disease: A Qualitative Interview Study"],"prefix":"10.1007","volume":"41","author":[{"given":"Ewelina","family":"Palmer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ichha","family":"Johar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dustin J.","family":"Little","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niklas","family":"Karlsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,9]]},"reference":[{"key":"2853_CR1","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical practice guideline for the evaluation and management of chronic kidney disease. 2013. https:\/\/kdigo.org\/wp-content\/uploads\/2017\/02\/KDIGO_2012_CKD_GL.pdf. Accessed 4 Apr 2023."},{"issue":"11","key":"2853_CR2","doi-asserted-by":"publisher","first-page":"825","DOI":"10.7326\/0003-4819-158-11-201306040-00007","volume":"158","author":"PE Stevens","year":"2013","unstructured":"Stevens PE, Levin A. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Ann Intern Med. 2013;158(11):825\u201330.","journal-title":"Ann Intern Med"},{"issue":"10225","key":"2853_CR3","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/S0140-6736(20)30045-3","volume":"395","author":"GBD Chronic Kidney Disease Collaboration","year":"2020","unstructured":"GBD Chronic Kidney Disease Collaboration. Global, regional, and national burden of chronic kidney disease, 1990\u20132017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2020;395(10225):709\u201333.","journal-title":"Lancet"},{"issue":"10159","key":"2853_CR4","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1016\/S0140-6736(18)31694-5","volume":"392","author":"KJ Foreman","year":"2018","unstructured":"Foreman KJ, Marquez N, Dolgert A, et al. Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016\u201340 for 195 countries and territories. Lancet. 2018;392(10159):2052\u201390.","journal-title":"Lancet"},{"issue":"1","key":"2853_CR5","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/s41572-018-0047-y","volume":"4","author":"C Bergmann","year":"2018","unstructured":"Bergmann C, Guay-Woodford LM, Harris PC, Horie S, Peters DJM, Torres VE. Polycystic kidney disease. Nat Rev Dis Primers. 2018;4(1):50.","journal-title":"Nat Rev Dis Primers"},{"issue":"1","key":"2853_CR6","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1186\/s12882-021-02440-9","volume":"22","author":"JE Flythe","year":"2021","unstructured":"Flythe JE, Karlsson N, Sundgren A, et al. Development of a preliminary conceptual model of the patient experience of chronic kidney disease: a targeted literature review and analysis. BMC Nephrol. 2021;22(1):233.","journal-title":"BMC Nephrol"},{"issue":"11","key":"2853_CR7","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1177\/2040622318785575","volume":"9","author":"HJ MacKinnon","year":"2018","unstructured":"MacKinnon HJ, Wilkinson TJ, Clarke AL, et al. The association of physical function and physical activity with all-cause mortality and adverse clinical outcomes in nondialysis chronic kidney disease: a systematic review. Ther Adv Chronic Dis. 2018;9(11):209\u201326.","journal-title":"Ther Adv Chronic Dis"},{"issue":"2","key":"2853_CR8","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/S1073-4449(99)70028-2","volume":"6","author":"P Painter","year":"1999","unstructured":"Painter P, Stewart AL, Carey S. Physical functioning: definitions, measurement, and expectations. Adv Ren Replace Ther. 1999;6(2):110\u201323.","journal-title":"Adv Ren Replace Ther"},{"issue":"12","key":"2853_CR9","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.2215\/CJN.01970309","volume":"4","author":"S Beddhu","year":"2009","unstructured":"Beddhu S, Baird BC, Zitterkoph J, Neilson J, Greene T. Physical activity and mortality in chronic kidney disease (NHANES III). Clin J Am Soc Nephrol. 2009;4(12):1901\u20136.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"8","key":"2853_CR10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0183642","volume":"12","author":"Y Tsai","year":"2017","unstructured":"Tsai Y, Chen H, Hsiao S, et al. Association of physical activity with cardiovascular and renal outcomes and quality of life in chronic kidney disease. PLoS ONE. 2017;12(8):e0183642.","journal-title":"PLoS ONE"},{"issue":"1","key":"2853_CR11","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1186\/s12882-021-02591-9","volume":"22","author":"MB Weber","year":"2021","unstructured":"Weber MB, Ziolkowski S, Bootwala A, Bienvenida A, Anand S, Lobelo F. Perceptions of physical activity and technology enabled exercise interventions among people with advanced chronic kidney disease: a qualitative study. BMC Nephrol. 2021;22(1):373. https:\/\/doi.org\/10.1186\/s12882-021-02591-9.","journal-title":"BMC Nephrol"},{"issue":"3","key":"2853_CR12","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1093\/ndt\/gfr404","volume":"27","author":"C Delgado","year":"2012","unstructured":"Delgado C, Johansen KL. Barriers to exercise participation among dialysis patients. Nephrol Dial Transplant. 2012;27(3):1152\u20137. https:\/\/doi.org\/10.1093\/ndt\/gfr404.","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"2853_CR13","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1186\/s12882-016-0399-z","volume":"17","author":"M Jhamb","year":"2016","unstructured":"Jhamb M, McNulty ML, Ingalsbe G, et al. Knowledge, barriers and facilitators of exercise in dialysis patients: a qualitative study of patients, staff and nephrologists. BMC Nephrol. 2016;17(1):192. https:\/\/doi.org\/10.1186\/s12882-016-0399-z.","journal-title":"BMC Nephrol"},{"key":"2853_CR14","unstructured":"US Food and Drug Administration (FDA). Clinical Outcome Assessment (COA): frequently asked questions. 2020. https:\/\/www.fda.gov\/about-fda\/clinical-outcome-assessment-coa-frequently-asked-questions#COADefinition. Accessed 5 Jan 2023."},{"key":"2853_CR15","unstructured":"US Food and Drug Administration (FDA). Qualification process for drug development tools. 2020. https:\/\/www.fda.gov\/media\/133511\/download. Accessed 23 Jan 2023."},{"key":"2853_CR16","unstructured":"US Food and Drug Administration-US National Institutes of Health Biomarker Working Group (FDA-NIH). BEST (Biomarkers, EndpointS, and other Tools) resource. 2021. https:\/\/www.fdanews.com\/ext\/resources\/files\/2020\/11-24-20-BEST.pdf?1606261388. Accessed 20 Jan 2023."},{"issue":"6","key":"2853_CR17","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/j.jval.2015.08.006","volume":"18","author":"MK Walton","year":"2015","unstructured":"Walton MK, Powers JH 3rd, Hobart J, et al. Clinical outcome assessments: conceptual foundation-report of the ISPOR clinical outcomes assessment\u2014emerging good practices for outcomes research task force. Value Health. 2015;18(6):741\u201352.","journal-title":"Value Health"},{"key":"2853_CR18","unstructured":"US Food and Drug Administration (FDA). Patient-focused drug development: methods to identify what is important to patients guidance for industry, food and drug administration staff, and other stakeholders. 2022. https:\/\/www.fda.gov\/media\/131230\/download. Accessed 17 Jan 2023."},{"issue":"8","key":"2853_CR19","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1016\/j.jval.2011.06.013","volume":"14","author":"DL Patrick","year":"2011","unstructured":"Patrick DL, Burke LB, Gwaltney CJ, et al. Content validity-establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO good research practices task force report: part 2-assessing respondent understanding. Value Health. 2011;14(8):978\u201388.","journal-title":"Value Health"},{"issue":"4","key":"2853_CR20","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1159\/000355568","volume":"38","author":"PP Reese","year":"2013","unstructured":"Reese PP, Cappola AR, Shults J, et al. Physical performance and frailty in chronic kidney disease. Am J Nephrol. 2013;38(4):307\u201315.","journal-title":"Am J Nephrol"},{"issue":"2","key":"2853_CR21","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s10157-012-0681-8","volume":"17","author":"K Hiraki","year":"2013","unstructured":"Hiraki K, Yasuda T, Hotta C, et al. Decreased physical function in pre-dialysis patients with chronic kidney disease. Clin Exp Nephrol. 2013;17(2):225\u201331.","journal-title":"Clin Exp Nephrol"},{"issue":"8","key":"2853_CR22","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/j.jval.2011.06.014","volume":"14","author":"DL Patrick","year":"2011","unstructured":"Patrick DL, Burke LB, Gwaltney CJ, et al. Content validity-establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO good research practices task force report: part 1-eliciting concepts for a new PRO instrument. Value Health. 2011;14(8):967\u201377.","journal-title":"Value Health"},{"issue":"1","key":"2853_CR23","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1186\/s12882-022-02826-3","volume":"23","author":"A Ryd\u00e9n","year":"2022","unstructured":"Ryd\u00e9n A, Nolan S, Maher J, Meyers O, K\u00fcndig A, Bjursell M. Understanding the patient experience of chronic kidney disease stages 2\u20133b: a qualitative interview study with Kidney Disease Quality of Life (KDQOL-36) debrief. BMC Nephrol. 2022;23(1):201.","journal-title":"BMC Nephrol"},{"issue":"1","key":"2853_CR24","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1159\/000476072","volume":"137","author":"NJH Broers","year":"2017","unstructured":"Broers NJH, Martens RJH, Cornelis T, et al. Physical activity in end-stage renal disease patients: the effects of starting dialysis in the first 6\u00a0months after the transition period. Nephron. 2017;137(1):47\u201356.","journal-title":"Nephron"},{"key":"2853_CR25","unstructured":"World Health Organization (WHO). International classification of functioning, disability and health. 2001. https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/42407\/9241545429-eng.pdf?sequence=1&isAllowed=y. Accessed 19 Jan 2023."},{"issue":"3","key":"2853_CR26","first-page":"411","volume":"30","author":"K Krippendorf","year":"2004","unstructured":"Krippendorf K. Reliability in content analysis: some common misconceptions and recommendations. Hum Commun Res. 2004;30(3):411\u201333.","journal-title":"Hum Commun Res"},{"key":"2853_CR27","unstructured":"US Food and Drug Administration (FDA). Patient-focused drug development: collecting comprehensive and representative input. 2020. https:\/\/www.fda.gov\/media\/139088\/download. Accessed 20 Jan 2023."},{"issue":"7","key":"2853_CR28","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.2215\/CJN.09810913","volume":"9","author":"IR Chen","year":"2014","unstructured":"Chen IR, Wang SM, Liang CC, et al. Association of walking with survival and RRT among patients with CKD stages 3\u20135. Clin J Am Soc Nephrol. 2014;9(7):1183\u20139.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"12","key":"2853_CR29","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1001\/jama.2020.1382","volume":"323","author":"PF Saint-Maurice","year":"2020","unstructured":"Saint-Maurice PF, Troiano RP, Bassett DR Jr, et al. Association of daily step count and step intensity with mortality among US adults. JAMA. 2020;323(12):1151\u201360.","journal-title":"JAMA"},{"issue":"1","key":"2853_CR30","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0190033","volume":"13","author":"LA Rico-Uribe","year":"2018","unstructured":"Rico-Uribe LA, Caballero FF, Mart\u00edn-Mar\u00eda N, Cabello M, Ayuso-Mateos JL, Miret M. Association of loneliness with all-cause mortality: a meta-analysis. PLoS ONE. 2018;13(1):e0190033.","journal-title":"PLoS ONE"},{"issue":"15","key":"2853_CR31","doi-asserted-by":"publisher","first-page":"5797","DOI":"10.1073\/pnas.1219686110","volume":"110","author":"A Steptoe","year":"2013","unstructured":"Steptoe A, Shankar A, Demakakos P, Wardle J. Social isolation, loneliness, and all-cause mortality in older men and women. Proc Natl Acad Sci USA. 2013;110(15):5797\u2013801.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4","key":"2853_CR32","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003954","volume":"19","author":"BR Fletcher","year":"2022","unstructured":"Fletcher BR, Damery S, Aiyegbusi OL, et al. Symptom burden and health-related quality of life in chronic kidney disease: a global systematic review and meta-analysis. PLoS Med. 2022;19(4):e1003954.","journal-title":"PLoS Med"},{"issue":"1","key":"2853_CR33","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1186\/s12882-020-02063-6","volume":"21","author":"AC Nixon","year":"2020","unstructured":"Nixon AC, Wilkinson TJ, Young HML, et al. Symptom-burden in people living with frailty and chronic kidney disease. BMC Nephrol. 2020;21(1):411.","journal-title":"BMC Nephrol"},{"issue":"1","key":"2853_CR34","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1186\/s12889-020-09639-9","volume":"20","author":"A Phyo","year":"2020","unstructured":"Phyo A, Freak-Poli R, Craig H, et al. Quality of life and mortality in the general population: a systematic review and meta-analysis. BMC Public Health. 2020;20(1):1596.","journal-title":"BMC Public Health"},{"issue":"11","key":"2853_CR35","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0165675","volume":"11","author":"MD Jesky","year":"2016","unstructured":"Jesky MD, Dutton M, Dasgupta I, et al. Health-related quality of life impacts mortality but not progression to end-stage renal disease in pre-dialysis chronic kidney disease: a prospective observational study. PLoS ONE. 2016;11(11):e0165675.","journal-title":"PLoS ONE"},{"issue":"1","key":"2853_CR36","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1186\/s12877-021-02163-4","volume":"21","author":"RL Walker","year":"2021","unstructured":"Walker RL, Greenwood-Hickman MA, Bellettiere J, et al. Associations between physical function and device-based measures of physical activity and sedentary behavior patterns in older adults: moving beyond moderate-to-vigorous intensity physical activity. BMC Geriatr. 2021;21(1):216.","journal-title":"BMC Geriatr"},{"issue":"1","key":"2853_CR37","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1159\/000500668","volume":"50","author":"LP Gregg","year":"2019","unstructured":"Gregg LP, Jain N, Carmody T, et al. Fatigue in nondialysis chronic kidney disease: correlates and association with kidney outcomes. Am J Nephrol. 2019;50(1):37\u201347.","journal-title":"Am J Nephrol"},{"issue":"12","key":"2853_CR38","doi-asserted-by":"publisher","DOI":"10.2196\/11315","volume":"6","author":"V Agarwal","year":"2018","unstructured":"Agarwal V, Smuck M, Tomkins-Lane C, Shah NH. Inferring physical function from wearable activity monitors: analysis of free-living activity data from patients with knee osteoarthritis. JMIR Mhealth Uhealth. 2018;6(12):e11315.","journal-title":"JMIR Mhealth Uhealth"},{"key":"2853_CR39","unstructured":"Public Health England (PHE). Chronic kidney disease prevalence model. 2014. https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/612303\/ChronickidneydiseaseCKDprevalencemodelbriefing.pdf. Accessed 06 Jan 2023."},{"issue":"7","key":"2853_CR40","doi-asserted-by":"publisher","first-page":"473","DOI":"10.7326\/M16-0273","volume":"165","author":"D Murphy","year":"2016","unstructured":"Murphy D, McCulloch CE, Lin F, et al. Trends in prevalence of chronic kidney disease in the United States. Ann Intern Med. 2016;165(7):473\u201381.","journal-title":"Ann Intern Med"},{"issue":"7","key":"2853_CR41","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0158765","volume":"11","author":"NR Hill","year":"2016","unstructured":"Hill NR, Fatoba ST, Oke JL, et al. Global prevalence of chronic kidney disease\u2014a systematic review and meta-analysis. PLoS ONE. 2016;11(7):e0158765.","journal-title":"PLoS ONE"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-02853-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-024-02853-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-02853-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,28]],"date-time":"2024-06-28T10:26:41Z","timestamp":1719570401000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-024-02853-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,9]]},"references-count":41,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["2853"],"URL":"https:\/\/doi.org\/10.1007\/s12325-024-02853-6","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,9]]},"assertion":[{"value":"7 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ewelina Palmer, Dustin J. Little and Niklas Karlsson are employees of AstraZeneca and hold shares in AstraZeneca. Ichha Johar is an employee of IQVIA, which received funds from AstraZeneca to collect and analyse the study data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Ethics approval was obtained from the WIRB\u2013Copernicus Group Institutional Review Board in May\u00a02021 (study no. 1304203) for the qualitative interview research protocol, interview guide and all patient communication documents. The interviews were conducted in accordance with the recommended guidelines provided by the International Society for Pharmacoeconomics and Outcomes Research Good Research Practices Task Force and reflect the US Food and Drug Administration guidance on methods to identify what is important to patients. All participants provided informed consent online. Written informed consent for the publication of the patients\u2019 clinical details was obtained.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}